Nuvation Bio Granted Orphan Drug Designation for NUV-422 for Patients with Malignant Gliomas
NEW YORK, March 11, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet...
Nuvation Bio Granted Orphan Drug Designation for NUV-422 for Patients with Malignant Gliomas
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treat
GlaxoSmithKline doubles down on Vir pact, throwing in $345M upfront to go beyond COVID-19
Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company
Sana snags $587.5M IPO to catapult cell therapies into the clinic
Gilead Sciences and Gritstone Announce Collaboration For HIV Cure
Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID
Tessera Therapeutics Attracts Over $230M in Series B Financing to Advance ‘Gene Writing’
Top Life Sciences Startups to Watch in 2021